BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/27/2022 2:48:53 AM | Browse: 205 | Download: 292
 |
Received |
|
2022-01-17 12:34 |
|
Peer-Review Started |
|
2022-01-17 12:35 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-04-11 07:31 |
|
Revised |
|
2022-04-25 07:36 |
|
Second Decision |
|
2022-06-24 03:15 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-06-24 22:05 |
|
Articles in Press |
|
2022-06-24 22:05 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-06-22 17:01 |
|
Typeset the Manuscript |
|
2022-07-13 07:48 |
|
Publish the Manuscript Online |
|
2022-07-27 02:48 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Peroxisome proliferator-activated receptor gamma as a therapeutic target for hepatocellular carcinoma: Experimental and clinical scenarios
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Swati Katoch, Vinesh Sharma and Vikram Patial |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| CSIR, India |
MLP0204 |
|
| Corresponding Author |
Vikram Patial, PhD, Senior Scientist, Division of Dietetics and Nutrition Technology, Institute of Himalayan Bioresource Technology, NA, Palampur 176061, Himachal Pradesh, India. vikrampatial@ihbt.res.in |
| Key Words |
Anticancer; Hepatocellular carcinoma; Natural agonists; Peroxisome proliferator-activated receptor-γ; Thiazolidinediones |
| Core Tip |
Hepatocellular carcinoma (HCC) is the most common type of liver cancer worldwide. Viral infections and metabolic syndrome are the major risk factors for HCC, and its incidence is expected to increase to > 1 million cases annually by 2025. The crucial role of peroxisome-proliferator-activated receptor gamma (PPARγ) in HCC pathophysiology makes it a potential therapeutic target. Along with synthetic agonists, natural PPARγ agonists provide alternative and safer options for HCC treatment; however, they need to be validated clinically. This review discusses the regulatory role of PPARγ in HCC pathogenesis and experimental and clinical scenarios of PPARγ agonists in HCC treatment. |
| Publish Date |
2022-07-27 02:48 |
| Citation |
Katoch S, Sharma V, Patial V. Peroxisome proliferator-activated receptor-gamma as a therapeutic target for hepatocellular carcinoma: Experimental and clinical scenarios. World J Gastroenterol 2022; 28(28): 3535-3554 |
| URL |
https://www.wjgnet.com/1007-9327/full/v28/i28/3535.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v28.i28.3535 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
